Suppr超能文献

甲癣的危险因素和合并症:对局部治疗的启示

Risk Factors and Comorbidities for Onychomycosis: Implications for Treatment with Topical Therapy.

作者信息

Elewski Boni E, Tosti Antonella

机构信息

Department of Dermatology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama;

出版信息

J Clin Aesthet Dermatol. 2015 Nov;8(11):38-42.

Abstract

A number of comorbidities and risk factors complicate the successful management of onychomycosis. Underlying conditions and patient characteristics, such as tinea pedis, age, and obesity, contribute to risk, whereas comorbidities, such as diabetes and psoriasis, can increase susceptibility to the disease. There are limited data on treatment effectiveness in these patients. Here, the authors review post hoc analyses of efinaconazole topical solution, 10%, in mild-to-moderate onychomycosis and present new data in terms of age and obesity. The only post hoc analysis to report significant differences so far is gender, where female patients do much better; however, the reasons are unclear. The authors report significant differences in terms of efficacy in obese patients who do not respond as well as those with normal body mass index (P=0.05) and in patients who have their co-existing tinea pedis treated compared to those in whom co-existing tinea pedis was not treated (P=0.025). Although there is a trend to reduced efficacy in older patients and those with co-existing diabetes, differences were not significant. More research is needed in onychomycosis patients with these important risk factors and comorbidities to fully evaluate the treatment challengse and possible solutions.

摘要

多种合并症和风险因素使甲癣的成功治疗变得复杂。潜在疾病和患者特征,如足癣、年龄和肥胖,会增加患病风险,而糖尿病和银屑病等合并症会增加对该病的易感性。关于这些患者的治疗效果的数据有限。在此,作者回顾了10%的艾氟康唑外用溶液治疗轻至中度甲癣的事后分析,并给出了关于年龄和肥胖的新数据。迄今为止,唯一报告有显著差异的事后分析是性别,女性患者的治疗效果要好得多;然而,原因尚不清楚。作者报告称,肥胖患者与体重指数正常的患者相比,疗效存在显著差异(P=0.05),同时,合并足癣接受治疗的患者与未接受治疗的患者相比,疗效也存在显著差异(P=0.025)。尽管老年患者和合并糖尿病的患者有疗效降低的趋势,但差异并不显著。对于患有这些重要风险因素和合并症的甲癣患者,需要开展更多研究,以全面评估治疗挑战和可能的解决方案。

相似文献

2
5
Management of onychomycosis and co-existing tinea pedis.
J Drugs Dermatol. 2015 May;14(5):492-4.
6
Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients.
Expert Rev Anti Infect Ther. 2022 Jan;20(1):3-15. doi: 10.1080/14787210.2021.1939011. Epub 2021 Jun 30.
7
Efinaconazole in Onychomycosis.
Am J Clin Dermatol. 2022 Mar;23(2):207-218. doi: 10.1007/s40257-021-00660-1. Epub 2021 Dec 13.
9
Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis.
Med Mycol J. 2019;60(3):71-74. doi: 10.3314/mmj.19.006.

引用本文的文献

5
Retrospective Analysis of Onychomycosis Risk Factors Using the 2003-2014 National Inpatient Sample.
Dermatol Pract Concept. 2024 Apr 1;14(2):e2024074. doi: 10.5826/dpc.1402a74.
6
Toenail Onychomycosis with or without Diabetes in Canada: Patient Treatment Preferences and Health State Utilities.
Patient Prefer Adherence. 2024 Feb 22;18:475-486. doi: 10.2147/PPA.S450215. eCollection 2024.
7
Prevalence and risk predictors of onychomycosis in patients on hemodialysis: an observation, prospective, and unicenter study in Brazil.
Front Med (Lausanne). 2023 Nov 23;10:1268324. doi: 10.3389/fmed.2023.1268324. eCollection 2023.
10
Risk factors of dermatophytosis among Korean adults.
Sci Rep. 2022 Aug 4;12(1):13444. doi: 10.1038/s41598-022-17744-5.

本文引用的文献

2
4
Skin and nail mycoses in patients with diabetic foot.
G Ital Dermatol Venereol. 2013 Dec;148(6):603-8.
5
The impact of nail disorders on quality of life.
Eur J Dermatol. 2013 May-Jun;23(3):366-71. doi: 10.1684/ejd.2013.2048.
6
Onychomycosis as a warning sign for peripheral arterial disease.
Acta Derm Venereol. 2013 Nov;93(6):747-8. doi: 10.2340/00015555-1576.
7
Quality of life in patients with toenail onychomycosis.
Mycoses. 2013 Sep;56(5):543-51. doi: 10.1111/myc.12072. Epub 2013 Mar 18.
8
Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.
J Am Acad Dermatol. 2013 Apr;68(4):600-608. doi: 10.1016/j.jaad.2012.10.013. Epub 2012 Nov 20.
9
Onychomycosis in immunosuppressed children receiving chemotherapy.
Pediatr Dermatol. 2014 Sep-Oct;31(5):618-20. doi: 10.1111/pde.12030. Epub 2012 Oct 29.
10
Frequency of peripheral arterial disease and venous insufficiency in toenail onychomycosis.
J Dermatol. 2013 Feb;40(2):107-10. doi: 10.1111/1346-8138.12020. Epub 2012 Oct 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验